Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 4Standard of Care 3Specimen Handling 3Practice Guidelines as Topic 3Interviews as Topic 3Immunoenzyme Techniques 3Docetaxel 3raltitrexed 2Vincristine 2Trabectedin 2N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide 2Irinotecan 2Immunohistochemistry 2Gemcitabine 2Etoposide 2Early Intervention, Educational 2Bortezomib 2AEG 35156 2temsirolimus 1sabarubicin 1pembrolizumab 1nintedanib 1halofuginone 1ascrinvacumab 1Triptorelin Pamoate 1Thrombopoietin 1Theophylline 1SB939 compound 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × ascrinvacumab × Other solid neoplasm × Clear all
NCT01486368 2023-08-04

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2 Completed
17 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡